Peptide therapeutics require specific billing codes for insurance reimbursement. This reference provides HCPCS/CPT codes, ICD-10 diagnosis codes, prior authorization pathways, and reimbursement optimization strategies for major peptide classes.
| Product | HCPCS Code | Description | Medicare Coverage |
|---|
| Semaglutide (Ozempic) | J3490 (unclassified drug) | T2D indication | Covered (Part D) |
| Semaglutide (Wegovy) | J3490 (unclassified drug) | Obesity indication | Limited |
| Liraglutide (Victoza) | J3490 (unclassified drug) | T2D indication | Covered (Part D) |
| Dulaglutide (Trulicity) | J3490 (unclassified drug) | T2D indication | Covered (Part D) |
| Tirzepatide (Mounjaro) | J3490 (unclassified drug) | T2D indication | Covered (Part D) |
| Tirzepatide (Zepbound) | J3490 (unclassified drug) | Obesity indication | Limited |
| Exenatide (Byetta) | J3490 (unclassified drug) | T2D indication | Covered (Part D) |
| Exenatide ER (Bydureon) | J3490 (unclassified drug) | T2D indication | Covered (Part D) |
Note: GLP-1 RAs are typically covered under Medicare Part D (prescription drug benefit), not Part B (medical benefit). HCPCS code J3490 is used for drugs not otherwise classified; specific product codes may vary by payer.
| Product | HCPCS Code | Description | Medicare Coverage |
|---|
| Insulin glargine (Lantus) | J1817 | Insulin glargine, 100 units | Covered (Part D) |
| Insulin glargine biosimilar | J1817 | Biosimilar glargine | Covered (Part D) |
| Insulin lispro (Humalog) | J1817 | Insulin lispro, 100 units | Covered (Part D) |
| Insulin aspart (NovoRapid) | J1817 | Insulin aspart, 100 units | Covered (Part D) |
| Insulin degludec (Tresiba) | J1817 | Insulin degludec, 100 units | Covered (Part D) |
| Insulin detemir (Levemir) | J1817 | Insulin detemir, 100 units | Covered (Part D) |
Note: Insulins are covered under Part D for Medicare patients. For patients with commercial insurance, insulins are covered under the prescription drug benefit.
| Product | HCPCS Code | Description | Indication |
|---|
| Octreotide (Sandostatin) | J1817 | Octreotide, 100 µg | Acromegaly |
| Octreotide LAR | J1817 | Octreotide LAR, 10 mg | Acromegaly |
| Leuprolide (Lupron) | J1950 | Leuprolide, 3.75 mg | Prostate cancer |
| Goserelin (Zoladex) | J1950 | Goserelin, 3.6 mg implant | Prostate/breast cancer |
| Vasopressin | J3490 | Vasopressin, 10 units | Diabetes insipidus |
| Desmopressin (DDAVP) | J3490 | Desmopressin, 4 µg | Diabetes insipidus |
| Calcitonin (Miacalcin) | J3490 | Calcitonin, 200 IU | Paget’s disease |
| Glucagon | J3490 | Glucagon, 1 mg | Hypoglycemia |
| Code | Description | Coverage Implication |
|---|
| E11.0 | T2D with hyperglycemia | Covered |
| E11.1 | T2D with ketoacidosis | Covered |
| E11.3 | T2D with complications | Covered |
| E11.5 | T2D with circulatory complications | Covered |
| E11.6 | T2D with other complications | Covered |
| E11.8 | T2D with unspecified complications | Covered |
| E11.9 | T2D without complications | Covered |
| Code | Description | Coverage Implication |
|---|
| E66.0 | Obesity due to excess calories | Limited coverage |
| E66.1 | Morbid obesity | Limited coverage |
| E66.2 | Morbid obesity with alveolar hypoventilation | Limited coverage |
| E66.9 | Obesity, unspecified | Limited coverage |
| Z68.30–Z68.45 | BMI codes (30.0–45.0+) | Documentation |
Key Issue: Medicare Part D does not cover anti-obesity medications. Commercial coverage varies widely by plan.
| Code | Description | Coverage Implication |
|---|
| E23.0 | Hypopituitarism | Covered (GH) |
| E22.2 | Insufficient secretion of ADH | Covered (desmopressin) |
| Z79.3 | Long-term hormone replacement | Documentation |
| Code | Description | Coverage Implication |
|---|
| E21.1 | Acromegaly with tumor | Covered (octreotide) |
| E21.0 | Hyperpituitarism | Covered |
| Code | Description | Coverage Implication |
|---|
| C61 | Malignant neoplasm of prostate | Covered (leuprolide) |
| Z85.46 | Personal history of prostate cancer | Documentation |
| Criterion | Requirement | Documentation |
|---|
| Diagnosis | T2D (E11.x) | ICD-10 code |
| HbA1c | ≥7.0% (some plans ≥7.5%) | Lab result |
| Trial of metformin | 90 days | Prescription records |
| BMI (obesity) | ≥30 (or ≥27 with comorbidities) | Medical record |
| Comorbidities | HTN, dyslipidemia, OSA, CVD | Diagnosis codes |
| Prescriber | MD, DO, NP, PA | Prescriber credentials |
| Criterion | Requirement | Documentation |
|---|
| Diagnosis | T1D or T2D | ICD-10 code |
| HbA1c | ≥7.0% | Lab result |
| Trial of OADs | 90 days (T2D) | Prescription records |
| Type of insulin | Long-acting, rapid-acting | Medical necessity |
| Dose verification | Current regimen | Prescription |
- Diagnosis codes: Always link the appropriate ICD-10 code to the HCPCS code.
- Medical necessity: Document clinical rationale for the specific peptide selected.
- Trial and failure: Document trials of preferred agents before requesting non-preferred agents.
- Comorbidities: Include all relevant comorbidities to support medical necessity.
- BMI documentation: For obesity indications, include BMI codes (Z68.x) with the weight class.
| Denial Reason | Appeal Strategy |
|---|
| Step therapy failure | Document prior therapy trials and failures |
| Medical necessity | Provide clinical evidence supporting peptide selection |
| Non-formulary | Request formulary exception with clinical rationale |
| Prior auth expired | Re-submit with updated clinical documentation |
| Dose exceeds limit | Document titration rationale and response |
| Strategy | Description |
|---|
| Manufacturer coupons | Most GLP-1 RA manufacturers offer savings cards |
| Patient assistance programs | Available for uninsured/underinsured patients |
| 340B pricing | Available for covered entities |
| Biosimilar substitution | Use biosimilar insulins when available |
| Combination therapy | Combine with OADs to reduce peptide dose |
| Coverage | Part D | Part B |
|---|
| GLP-1 RAs | Covered (obesity excluded) | Not covered |
| Insulins | Covered | Covered (some) |
| Injectable peptides | Covered | Covered (some) |
| Self-administered | Covered (Part D) | Not covered |
| Physician-administered | Not covered | Covered (Part B) |
| Oral peptides | Covered | Not covered |
Key Distinction: Self-administered peptides (GLP-1 RAs, insulins) are covered under Part D. Physician-administered peptides (octreotide, leuprolide injections) may be covered under Part B.
Peptide reimbursement requires careful navigation of HCPCS codes, ICD-10 diagnosis codes, and prior authorization requirements. GLP-1 RAs face coverage limitations for obesity indications, while diabetes indications are generally covered under Medicare Part D. The reimbursement landscape is evolving, with emerging peptides and biosimilars creating new coding and coverage challenges. Optimization requires thorough documentation, strategic appeal of denials, and utilization of manufacturer assistance programs.
